"The singular message to the public is that the optimal treatment for multivessel coronary artery disease—to improve not only long-term survival but also lower your risk of complications—is coronary artery bypass surgery," one specialist said in a statement. 

The new recall includes nearly 4,500 devices. There have been 134 incidents so far, including 5 adverse events.  

The newly approved SGLT2 inhibitor, bexagliflozin, is marketed under the name Brenzavvy. It is not recommended for patients with type 1 diabetes. 

Even if symptoms disappear quickly, a transient ischemic attack can be a major short-term risk indicator.

Researchers examined data from nearly 2 million patients, sharing their full findings in JACC: Cardiovascular Imaging.

Overwhelmed or confused by AI and machine learning technology? A new analysis in European Heart Journal hopes to provide some clarity. 

Early mortality specifically related to complications during the TLR procedure was quite rare.